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 Abbreviations 
 ADC  Apparent diffusion coeffi cient 
 CHTH  Chemotherapy 
 DCE  Dynamic contrast-enhanced MRI 
 DSC  Dynamic susceptibility contrast 
 DSS  Decision support system 
 DWI  Diffusion-weighted imaging 
 EHR  Electronic health record 
 GB  Glioblastoma 
 GUI  Graphical user interface 
 Kep  Contrast extraction coeffi cient 
 Ktrans  Volume transfer coeffi cient 
 MR  Magnetic resonance 
 MRI  Magnetic resonance imaging 
 MRSI  Magnetic resonance spectroscopy 
imaging 
 NGS  Next-generation sequencing 
 PET  Positron emission tomography 
 PWI  Perfusion-weighted imaging 
 RCBV  Relative cerebral blood volume 
 RT  Radiotherapy 
 TMZ  Temozolomide 
 UX  User experience 
 WHO  World Health Organization 
16.1  Introduction 
 Glioblastoma (GB) implies a devastating progno-
sis with an average survival of 14–16 months 
using the current standard of care treatment [ 1 ]. 
GB is the most frequent malignant tumour origi-
nating from the brain parenchyma, and it is char-
acterised by a marked intratumoural heterogeneity, 
proneness to infi ltrate throughout the brain paren-
chyma, robust angiogenesis and necrosis as well 
as intense resistance to apoptosis and genomic 
instability [ 2 ]. 
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 Up till now, treatment and follow-up of GB 
remains one of the most challenging tasks in clini-
cal oncology. The critical points in GB manage-
ment are related to neurosurgical and radiotherapy 
(RT) planning and early-response-to-therapy 
assessment. These points link with (1) maximum 
safe resection of the tumour; (2) local RT dose 
value, distribution and technique; (3) histopathol-
ogy diagnosis in terms of GB molecular charac-
terisation; and (4) duration of adjuvant 
chemotherapy (CHTH) and best treatment during 
follow-up. 
 Recently, important advances have been 
made in the multiscale (molecular-cellular-
tissue- patient) study of GB through the identifi -
cation of parallel and dynamic tumour markers 
by  techniques such as next-generation sequenc-
ing (NGS), immunohistochemistry characteri-
sation, radiogenomics, multi-parametric images 
and circulating biomarkers from liquid biopsies. 
These have led to the defi nition of different 
molecular subtypes of GB, with prognostic and 
predictive- of- response implications [ 3 ], 
although this molecular classifi cation is not 
actually extended in the clinical practice. 
 Additionally, the number of imaging modali-
ties and associated imaging biomarkers available 
for the assessment of patients is considerably 
high and probably will grow in the following 
years. These include perfusion-weighted imag-
ing (PWI), diffusion-weighted imaging (DWI), 
magnetic resonance spectroscopy imaging 
(MRSI) and positron emission tomography 
(PET). Although the added value of medical 
imaging in GB diagnostic, prognostic and treat-
ment assessment is unmistakable, it has been 
demonstrated that no single modality in itself is 
specifi c enough to reveal the early response to 
treatment of GB tumours due to their heteroge-
neity and rapid evolution [ 4 ]. 
 In this setting, decision-making requires the 
joint analysis of complex data acquired through-
out the treatment and follow-up process, includ-
ing molecular biomarkers, imaging biomarkers 
and clinical data. Moreover, a comprehensive 
analysis of the data acquired from the patient 
requires taking into account the three main 
dimensions of GB data: multilevel dimension, 
from voxel to population-based subtypes; multi-
scale dimension, from molecular to tissue scale; 
and temporal dimension, from single to longitu-
dinal studies. 
 To support the analysis of these complex data, 
in recent years, signifi cant advances have been 
made in the development of automated medical 
image analysis tools for brain tumours. These 
tools are able to generate automated segmenta-
tions of the different GB-related tissues (i.e. 
oedema, enhancing tumour, necrosis), hypoxia 
maps and other useful nosological images. The 
last decade has also witnessed increased research 
efforts in the fi eld of multiscale cancer modelling 
including the development of in silico (i.e. on the 
computer) oncology models able to simulate 
 different therapy outcomes based on the individ-
ual patient information. 
 The purpose of this chapter is not only to 
introduce the role of imaging biomarkers in the 
GB management but also to identify and intro-
duce the new trends that will contribute to the 
successful inclusion of these biomarkers in an 
integrative multiscale analysis. To do so, this 
chapter will focus on (1) the description of the 
standard clinical workfl ow based on accepted 
clinical guidelines, (2) the identifi cation of the 
main open questions in GB management, (3) the 
role of imaging biomarkers in GB management 
and (4) the introduction of the new trends in GB 
management. 
 Moreover, this chapter introduces an approach 
of how these new trends could be integrated in 
the complex scenario of multidisciplinary teams 
enabling the access and analysis of multiscale 
and multilevel data. This approach is based on a 
modular clinical decision support system (DSS) 
architecture for GB management to easily include 
and actualise analytic modules. Moreover, an 
overview of the integration strategy based on user 
experience (UX) is described to ensure the 
acceptability of the DSS by the multidisciplinary 
clinical community. 
 Potential clinical benefi ts of incorporating this 
knowledge in the tumour board meetings include 
advances in surgery and RT planning, adjuvant 
treatment selection, assessment of response, 
early recurrence detection and selection of subse-
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quent therapies. Moreover, this integrated 
approach will contribute to a better characterisa-
tion of GB subgroups, identifi cation of new cir-
culating biomarkers and identifi cation of new 
targets for the treatment of patients with GB. 
16.2  The Standard Clinical 
Workﬂ ow 
 Primary treatment after clinical or radiological 
evidences suggesting existence of GB consists on 
the maximum safe tumour resection based on the 
neurosurgical feasibility study. The extension of 
the tumour resection should be confi rmed by 
postoperative magnetic resonance imaging (MRI) 
scan within 72 h after surgery, with and without 
contrast [ 5 ]. In case the resection is not recom-
mended, a stereotactic or open biopsy or subtotal 
resection should be performed to establish the 
diagnosis. As soon as the pathology is available, 
the tumour expert panel or tumour board consul-
tation is recommended. 
 After surgical intervention, the standard of 
care for newly diagnosed GB consists of adju-
vant chemo-radiation therapy. In particular, 
surgery should be followed by RT and concur-
rent temozolomide (TMZ) CHTH and followed 
by six cycles of adjuvant TMZ. In the case of 
signifi cant improvement on therapy, the inclu-
sion of additional cycles of TMZ could be 
considered. 
 After the completion of RT, the follow-up of 
patients will consist on serial MRI scans. These 
MRI scans will be done in the second and sixth 
weeks (after RT), then every 2–4 months for 2–3 
years and then less frequently [ 5 ]. The use of 
complementary imaging modalities such as 
MRSI, PWI or PET can be considered to facili-
tate the differentiation between pseudoprogres-
sion and radiation-induced necrosis. 
 In the case of local recurrence, a second resec-
tion is encouraged whenever it is possible. 
Following re-resection, or if the local recurrence 
is unresectable, poor prognosis patients should 
undergo best supportive care without further 
active treatment [ 5 ]. In case of diffuse or multiple 
recurring lesions, the options include surgery to 
reduce mass effect, the administration of sys-
temic CHTH and best supportive care for poor 
prognosis patients. 
 The temporal diagram of the treatment and 
follow-up of GB patients is presented in 
Fig.  16.1 .
 Fig. 16.1  Temporal diagram of the treatment and follow-
 up of GB patients including (1) the available clinical 
information at each stage, (2) the treatments (in  blue ) and 
(3) the main clinical decisions (in  orange ). RT dose dist. 
mean the information about the radiotherapy dose distri-
bution. Q4.n and MR3.n mean the successive decisions 
and image acquisitions done during the follow-up, 
respectively 
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16.3  Main Questions 
in Glioblastoma 
Management 
 Based on the above-mentioned standard clinical 
workfl ow, we could identify the following main 
steps in standard treatment for GB:
•  Presurgery: to generate a fi rst diagnosis based 
on medical imaging information 
•  Surgery: to remove the maximum safe area 
suspected to be affected by the tumour and to 
analyse the resected tissue to generate a more 
accurate diagnosis 
•  Concomitant RT with CHTH (based on TMZ): 
to irradiate the tumour tissue and to avoid the 
fast propagation of the tumour cells 
•  Follow-up including CHTH as adjuvant treat-
ment to avoid the fast propagation of the 
tumour cells 
 In each of these four steps, important clinical 
decisions have to be addressed in order to select 
the most adequate treatment for each individual 
patient. Among them, the key decisions in GB 
diagnosis, therapy and follow-up are presented in 
the following subsections: 
16.3.1  Presurgery Decision 
 What is the precise extension of the tumour that 
determines the maximum area that can be safely 
resected? Surgery of GB is by defi nition incom-
plete given the diffuse infi ltrative nature of the 
tumour and the inability to remove it entirely 
without causing too much harm to the healthy 
brain. A major challenge in therapy of GB is the 
selection of the area for maximum safe resection 
of the tumour in order to reduce the degree and 
time to tumour recurrence while at the same time 
affecting the patient functionality as less as pos-
sible [ 6 ]. 
16.3.2  Post-surgery Decision 
 What is the molecular subtype of GB? What are 
the implications of GB subtyping in patient prog-
nosis, treatment and follow-up? In recent years, 
analysis of genomics, transcriptomics and pro-
teomics have identifi ed subtypes of GB with 
prognostic implications and different responses to 
treatment. After surgery, it is possible to charac-
terise the molecular subtype of GB using high- 
throughput arrays and immunohistochemistry 
techniques. Moreover, liquid biopsy may provide 
a wide set of biomarkers related to diagnosis, 
prognosis and treatment response. These bio-
markers can circumvent problems of tumour het-
erogeneity and can be obtained to monitor tumour 
changes over time. It is now fully clear that differ-
ent genetic subtypes of GB exist, associated with 
differences in molecular pathways involved and 
in biological behaviour. Therefore, clinical ques-
tions related to the prognosis and treatment 
response will be analysed in the context of knowl-
edge of the molecular and genetic underpinnings. 
16.3.3  Pre-radiotherapy Decision 
 What are the best RT dose value, distribution and 
technique for a specifi c patient? Currently the RT 
dose is estimated homogeneously based on ana-
tomical images from PET or magnetic resonance 
(MR) scanners. The challenge in the use of RT is 
to reduce the margins beyond the conventional 
clinical target volume to the minimum in order to 
have optimised planning target volumes in accor-
dance with the ICRU 62 defi nitions [ 7 ]. A reduc-
tion of RT treatment region uncertainty and a 
better estimation of the RT dose distribution 
based on the integration of functional informa-
tion extracted from the images with dose painting 
could allow reduction of the radiation applied to 
brain functional areas where necessary and 
increase of radiation where possible, thereby 
improving the quality of life of the patients and 
their survival times. 
16.3.4  Follow-Up Decisions 
 Is the treatment working properly? What should 
be the duration of adjuvant CHTH? What is the 
best treatment management during follow-up? 
Accurate interpretation of MRI scans in terms of 
E. Fuster-Garcia et al.
185
the biological evolution of the tumour is an 
important issue for measuring treatment response 
both in the setting of clinical trials and in routine 
clinical care. However, the evaluation of the dis-
ease progression still remains a diffi cult task in 
the face of treatment modality. Pseudoprogression 
of tumour versus true progression has become a 
confusing issue after treatment with TMZ and 
RT. Radiation injury (radionecrosis) is a potential 
late complication of RT, especially focal high- 
dose RT, and can easily be confused with tumour 
progression. Differentiating the two entities is 
problematic and often requires long-term follow-
 up with standard MRI, clinical assessment and 
use of corticosteroids [ 1 ]. By contrast, pseudo-
responses may occur after angiogenesis-targeted 
therapies, as a consequence of changes in vascu-
lar permeability. In this sense, an early and accu-
rate assessment of treatment response will 
improve the decision on maintenance or discon-
tinuation of adjuvant CHTH, as well as the elec-
tion and timing of subsequent treatments, 
including second-line CHTH and new local 
therapies. 
16.4  Imaging Biomarkers 
in Glioblastoma 
Management 
 The development of imaging biomarkers is pro-
viding new insights into tumour behaviour that 
were not available from conventional medical 
imaging. Imaging biomarkers have demonstrated 
to be relevant for the assessment of tumour grad-
ing and response to therapy, without any spatial 
or temporal constraints. These imaging biomark-
ers are based on imaging modalities such as PWI, 
DWI, MRSI and PET. 
 The inclusion of PWI biomarkers characteris-
ing the presence and properties of angiogenesis, 
vasculogenesis and tumour vascular heterogene-
ity might improve tumour grading, prognosis and 
follow-up evaluation [ 8 – 10 ]. The complex mod-
elling of dynamic susceptibility contrast (DSC) 
MRI sequences has also allowed for the quantifi -
cation of tumour permeability and angiogenesis 
processes, through pharmacokinetic models of 
the lesion. 
 DWI may allow the cellularity of tumours to 
be graded noninvasively; because cells constitute 
a relative barrier to water diffusion, compared 
with extracerebral space, tumours that are more 
cellular are expected to show less of an increase 
in apparent diffusion coeffi cient (ADC) than 
tumours that are less cellular [ 15 ]. Diffusion ten-
sor imaging and diffusion kurtosis imaging are 
used to describe diffusion 3D variability by 
means of mean diffusivity, fractional anisotropy 
and mean kurtosis. Several studies suggest that 
diffusion tensor imaging allows not only to 
observe high cellularity regions but also to evalu-
ate tumour invasion into the surrounding tissue 
[ 16 ]. Studies of patients with brain tumours have 
shown that increases in water diffusion generally 
indicate positive response to therapy [ 15 ]. 
 MRSI provides information regarding the 
concentration of specifi c metabolites throughout 
the brain, which has proven to be relevant in 
brain tumour diagnosis and prognosis. Thus, 
increased lipid levels are found in high-grade 
gliomas, indicating the presence of necrosis, 
which is a hallmark of GB [ 17 ]. Choline has been 
related to cell membrane density and is recog-
nised as a marker of cell proliferation [ 17 ]. 
Statistically signifi cant higher metabolite ratios 
of choline/creatine and choline/NAA have been 
reported in high-grade gliomas compared to low- 
grade gliomas [ 18 ]. Elevated choline levels have 
been found in peritumoural oedema surrounding 
GB, suggesting tumour invasion. After treatment, 
MRSI has also shown potential to differentiate 
tumour recurrence from radiation necrosis [ 19 ]. 
 Several PET tracers have shown their added 
value when it comes to the diagnosis, prognosis 
and treatment monitoring of brain tumours. 
18 F-FDG, which is a marker of glucose metabo-
lism, has shown correlation with tumour grade 
and survival rate in gliomas [ 20 ]. Increased 
amino acid PET tracer uptake has been related to 
angiogenesis and increased cell metabolism 
within gliomas, resulting in a higher 11C-MET 
uptake in high-grade than in low-grade gliomas 
[ 21 ]. Labelled nucleotides such as 18 F-FLT are 
indicators of cellular proliferation, promoting 
18 F-FLT kinetic analyses to assess early treat-
ment response [ 22 ]. 18 F-FMISO is a hypoxia 
marker, showing increased uptake in high-grade 
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but not in low-grade gliomas. Tumour progres-
sion and survival after RT have been related to 
18 F-FMISO uptake levels [ 23 ]. 
 Hypoxia plays a central role in tumour devel-
opment, angiogenesis, growth and resistance to 
treatment. Hypoxia measurements have been 
shown to correlate with the probability of meta-
static spread, tumour recurrence, resistance to 
CHTH and radiation, invasion and decreased 
patient survival. Only a few imaging techniques 
have potential for in vivo assessment of hypoxia 
in humans, particularly for repeated, sequential 
measurements [ 24 ]. These methods use either 
PET tracers or MRI techniques sensitive to varia-
tions in local oxygen changes such as blood oxy-
genation level-dependent MRI (BOLD-MRI) or 
dynamic contrast-enhanced MRI (DCE-MRI)). 
An additional approach to map regional hypoxia 
is through the use of 3D MRSI and the quantifi -
cation of lactate to N-acetyl-aspartate ratio with 
long echo times. 
 Although the added value of PWI, DWI, 
MRSI and PET is unmistakable, it has become 
clear that no single modality in itself is specifi c 
enough to show the early response to treatment of 
GB tumours due to their heterogeneity and evolu-
tion speed [ 4 ]. Hence, some groups have studied 
the complementary information provided by dif-
ferent modalities and techniques. Laimon et al. 
described the complementarity regarding tumour 
progression and response of dynamic [18 F] fl uo-
rothymidine (F-18 FLT) PET, sodium (23Na) 
MRI and 3-T morphological MRI biomarkers. 
 Manual segmentation is still the gold standard 
for brain tumours in clinical practice; however it 
implies a time-consuming and user-dependent 
bias, prone to errors and with questionable repro-
ducibility. Signifi cant progresses have been made 
in automated brain tumour segmentation based 
on machine learning [ 25 – 27 ]. Brain Tumour 
Segmentation (BRATS) Challenge on MICCAI 
Conference revealed that machine learning per-
forms well in the whole tumour segmentation 
compared to manual segmentation. However, 
supervised learning requires an expensive, time- 
consuming and biased task to retrieve a suffi -
ciently large set of labelled samples from which 
to learn discriminant functions for the posterior 
segmentation [ 26 ]. Moreover, spatio-temporal 
changes in clinical environment such as new MR 
machines, protocols or centres may distort the 
data and hence could affect the performance of 
the supervised models [ 28 ]. Unsupervised learn-
ing tackles these limitations in a more straight-
forward manner, as it directly learns the patient 
specifi c data to build an intra-patient segmenta-
tion model which is independent from the differ-
ences among patients [ 29 ]. 
16.5  New Trends for Integrated 
GB Management 
 Current clinical practices in GB management 
need to evolve to improve the poor results 
obtained to date in the treatment of this complex 
disease. To do so, the following promising 
approaches need to be particularly taken into 
account. 
16.5.1  GB Molecular Subtypes 
 In the last decade, genomic analyses, transcrip-
tomics and proteomics have identifi ed different 
GB subtypes and molecular pathways with impli-
cations for prognosis and treatment response. For 
optimal management of patients, more precise 
classifi cation of gliomas is needed, and molecu-
lar markers hold great promises in this respect. 
 The proneural subtype of GB, which is associ-
ated with better prognosis, is characterised by the 
expression of the histological markers OLIG2, 
DLL3, PDGFRA, IDH1 mutation (isocitrate 
dehydrogenase1), the absence of chromosomal 
gains or losses, the loss of TP53 heterozygosity 
and the normality of EGFR (epidermal growth 
factor receptor) as well as PTEN (phosphatase 
and tension homolog). The mesenchymal sub-
type, which corresponds to tumours of worse 
prognosis with strong angiogenic and infl amma-
tory features, is characterised by the expression 
of mesenchymal markers such as YKL-40, 
PECAM1 (CD31), VEGF and its receptors one 
and two, gain of chromosome 7, loss of PTEN, 
normal or extended EGFR and MET, 17q11.2 
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deletion as well as high expression of genes of 
the TNF superfamily and NF-kB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) 
signalling pathway. Other less consensual sub-
types are proliferative and classic, which share 
loss of PTEN and frequent EGFR amplifi cation. 
Proliferative subtype is characterised by histo-
logical markers, such as TOP2A and PCNA (pro-
liferative cell nuclear antigen), and loss of 
chromosome 10. The classic subtype harbours 
frequent amplifi cation of chromosome 7, loss of 
chromosome 10, amplifi cation of EGFR gene 
and absence of alterations in TP53, NF1, 
PDGFRA or IDH1 [ 3 ,  30 ,  31 ]. The neural sub-
type is characterised by neural markers. In retro-
spective studies, it was observed that classic and 
mesenchymal tumours benefi ted from combined 
treatment of RT plus TMZ, while in the proneu-
ral, TMZ did not seem to provide therapeutic 
benefi ts [ 3 ]. However, prospective studies are 
necessary to confi rm these fi ndings. 
 On the other hand, recent studies suggest that 
antiangiogenic therapy could be benefi cial in the 
proneural subtype and possibly in the prolifera-
tive subtype, but not in the mesenchymal [ 32 ]. 
All in all, it is currently clear that GB constitutes 
a ‘mixed bag’ of tumours and that the diagnosis 
of particular molecular subtypes (especially 
those characterised by mutations in IDH1/IDH2, 
H3F3A, BRAF, EGFR variant III (EGFRvIII) or 
EGFR amplifi cation) will be of relevance in daily 
clinical practice soon. 
 Given the complexity and costs of these stud-
ies, promising approaches endeavour to develop 
easy-to-use panels of workable tests in the clini-
cal context able to provide a more precise classi-
fi cation of gliomas, such as the analysis of 
messenger RNA (mRNA) by Colman and co- 
workers [ 8 ], which identifi es nine genes with 
prognostic value. Another study using immuno-
histochemistry methods used only three markers 
for the classifi cation in proneural-like and 
classical- like subtypes (p53, PDGFRA and 
EGFR) [ 33 ]. In addition, the expression of spe-
cifi c proteins, such as OLIG2, DLL3, TOP2A, 
CD44, VEGF and FOXG1, has been validated as 
a feature of GB molecular subtypes. Notably, 
activation of the signalling pathways pErk1,2/
pMAPK and pAKT has also shown its prognostic 
value in GB [ 9 ]. More recently, an innovative, 
minimal IHC-based scheme for GB subclass 
assignment was proposed in terms of positive 
staining for IDH1R132H for proneural, high- 
EGFR expression for the classical subtype and a 
combined high expression of PTEN, VIM and/or 
YKL40 for the mesenchymal subtype [ 10 ]. 
16.5.2  Key Enabling Molecular 
Biomarkers in the Clinical 
Practice 
 Tumour-derived molecular biomarkers include 
proteins, nucleic acids and tumour-derived extra-
cellular vesicles. These molecular biomarkers are 
mainly identifi ed in plasma, serum, blood plate-
lets, urine and/or cerebrospinal fl uid. These 
molecular biomarkers provide valuable informa-
tion of the mechanisms associated with cancer 
hallmarks such as cell proliferation, tumour pro-
gression, invasion, cell cycle, angiogenesis and 
apoptosis. Recently, circulating tumour cells 
have also been identifi ed in the blood of glioma 
patients. Circulating molecules, vesicles, 
‘tumour-educated’ platelets and cells may be 
useful as easily accessible diagnostic, prognostic 
and/or predictive biomarkers to guide the patient 
management. 
 There is an increasing interest in identifying 
the protein profi le of each GB subtype from 
peripheral blood samples, in addition to the 
immunohistochemical analysis of a small set of 
proteins for GB stratifi cation and the activation 
of key signalling pathways to identify potential 
therapeutic targets. A different hypothesis sug-
gests that the data obtained will allow the correla-
tion of a simple immunohistological classifi cation 
pattern with cell-free circulating proteins that 
may be used to predict prognosis as well as thera-
peutic response. If this hypothesis is confi rmed, it 
is expected that a wide perspective will be opened 
for identifying new and more effective therapeu-
tic targets. In this sense, advanced approaches 
aim to incorporate an accurate selection of 
molecular biomarkers (e.g. IHC, NGS, methyla-
tion status and chromosomal copy number aber-
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rations) including those obtained from liquid 
biopsy in the clinical management of GB (e.g. 
cell-free circulating proteins and RNA sequenc-
ing of ‘tumour-educated’ blood platelets). 
 Thereby, these approaches may help to cir-
cumvent problems related to tumour heterogene-
ity and sampling error at the time of diagnosis. If 
the success of these methodologies is confi rmed, 
it is expected that a wide perspective will be 
opened for identifying more informative bio-
markers with diagnostic, prognostic, predictive 
and/or monitoring value and innovative, more 
promising therapeutic targets. 
16.5.3  Advanced Multiscale Data 
Modelling in GB: In Silico 
Oncology Models 
 The main approaches for multiscale mathemati-
cal modelling of cancer have as a common start-
ing point the fact that cancer is a genetic disease 
and that its evolution is related, since the very 
early stage to mutations that give acquired abili-
ties in few or even single cells [ 34 ,  35 ]. The 
observation that the biological system under 
consideration has multiscale features has 
resulted in the development of mathematical 
models that essentially couple different models 
operating at different scales and that are able to 
cope with genomics, proteomics, cell-cell inter-
action, cell- environment interaction, release, dif-
fusion and absorption of chemical factors. 
Specifi cally, the modelling of cancer dynamics 
at the lowest scale, namely, molecular and cel-
lular scale, focuses on the critical changes within 
the cell that characterise cancer growth. These 
changes (i.e. self- suffi ciency in growth signals, 
insensitivity to antigrowth signals, evading 
apoptosis, limitless replicative potential, sus-
tained angiogenesis, evading immune system 
attack and tissue invasion and metastasis) incor-
porate some aspects of genetic mutation, gene 
expression and evolutionary selection, leading to 
malignant progression. In various cases, this 
evolution is induced by external or concomitant 
actions (as an example, the effect of therapies) 
[ 36 ]. At the tissue scale, macroscopic models of 
gliomas focus on the heterogeneous and aniso-
tropic characteristics of the brain-deducing mod-
els that are able to describe the growth of tumour 
masses and the diffusion of metastases in such 
an environment [ 37 ,  38 ]. 
 There are two major cancer-modelling 
schools that may be identifi ed: predominantly 
continuous and predominantly discrete models. 
Predominantly continuous models rely primarily 
on differential equations to describe processes 
such as diffusion of molecules, changes in 
tumour cell density and invasion of tumour cells 
into the surrounding tissue. Even the continuous 
mathematical models, which make use of partial 
ordinary differentiation equations and appropri-
ate boundary conditions, have to undergo discre-
tisation through the application of methods such 
as fi nite difference time domain or fi nite element 
techniques in order to practically deal with the 
high geometrical complexity of the biomechani-
cal problem. 
 A tumour growth modelling approach based 
solely on the continuous and/or fi nitised form of 
the diffusion’s reaction equation has a limited 
potential to effi ciently address the complexities 
of the treatment response phenomena in the mul-
tiscale context. The latter include inter alia the 
existence and dynamics of different proliferation 
potential cell categories (stem cells, limited 
mitotic potential cells, differentiated cells), dif-
ferent cell-cycle phases (G1, S, G2, M), different 
radiosensitivity and chemosensitivity profi les, 
different times spent within each cell-cycle 
phase, etc. 
 Discrete modelling has gained signifi cant 
momentum lately; it considers several discrete 
states in which cells may be found and possible 
transitions between them, governed by decision 
calculators, such as cytokinetic diagrams and 
agent-based techniques. Due to the hypercom-
plexity of cancer-related topics, each modelling 
approach is intrinsically able to successfully 
address only some of the aspects of this multifac-
eted problem. By combining the continuous and 
the discrete mathematical approaches, more 
comprehensive hybrid models addressing both 
glioma invasion and response to complex treat-
ment modalities could emerge. 
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 The ultimate goal of clinically oriented cancer 
simulation models is their eventual translation 
into clinical practice, which entails (a) thorough 
sensitivity analyses, in order to both comprehend 
and validate their behaviour, and at the same time 
gain further insight into the simulated mecha-
nisms, in a more quantitative way, and (b) an 
adaptation and validation process based on real 
clinical data [ 39 ]. On the global level, the fi rst 
large-scale, clinical trial-driven and clinically 
adaptable and testable oncosimulators have been 
developed by the In Silico Oncology and In Silico 
Medicine Group (ISO and ISMG) of the Institute 
of Communication and Computer Systems 
(ICCS), National Technical University of Athens 
(NTUA), in the context of the ACGT FP6 EU 
project ( http://acgt.ercim.eu/ ) for nephroblas-
toma and breast cancer within the framework of 
the SIOP 2001/GPOH ( http://www.siop-online.
org/ ) and the neoadjuvant trial of principle (TOP) 
clinical trials, respectively. 
16.6  Including Key Enabling 
Technologies in Clinical 
Practice 
 After reviewing the new trends in GB manage-
ment, we are ready to present an approach to 
cover the gap between the technologies (i.e. 
existing molecular GB subtyping techniques, 
multiscale-multilevel predictive models and bio-
marker images) and their integration in the clini-
cal workfl ow for the management of GB patients. 
 Our approach consists on the development of 
a clinical DSS to support multidisciplinary 
tumour boards in the therapy planning and early 
treatment response assessment of GB, that is, a 
health information technology system designed 
to assist the different actors involved in the GB 
management with main clinical decision-making 
tasks. The proposed DSS will use heterogeneous 
data to support and personalise treatment and 
follow-up for GB patients (see Fig.  16.2 ). The 
main functionalities to achieve this goal are:
 1.  Accessible and structured data: To be able to 
access the heterogeneous data in a transparent 
and secure way by developing interoperability 
and security layers. 
 2.  Generation of knowledge: The novel image 
analysis tools will generate segmentations of 
the GB extension, hallmark and nosological 
images and hypoxia mappings. The fi ndings 
obtained from imaging data together with 
molecular and clinical information will feed 
the multiscale-multilevel predictive models to 
obtain predictions of the evolution of the 
tumour depending on the simulated treatment. 
Finally an automatic characterisation of the 
GB molecular subtype will be done. 
 3.  Support to clinical decision: Once the knowl-
edge that addresses the clinical questions is 
generated, it will be used to support the clini-
cal decisions. The DSS will adapt the presen-
tation of their outputs to the clinical workfl ow. 
Two main scenarios have been considered: the 
fi rst one is the scenario where the clinician 
wants to access the DSS fi ndings using the 
hospital electronic health record (EHR) 
viewer. The DSS will include visualisation 
templates for EHR viewers tailored to each 
user profi le. The second one is the tumour 
board multidisciplinary scenario. In this sce-
nario, the DSS will facilitate a multidisci-
plinary collaborative interface including the 
latest visual and interactive technologies to 
improve user experience and acceptability. 
 A large body of evidence over many years 
suggests that DSS can be helpful in improving 
both clinical outcomes and adherence to 
evidence- based guidelines. However, to this day, 
clinical decision support systems are not widely 
used outside of a small number of sites, the main 
reasons being (1) the relative diffi culty of inte-
grating such systems into clinical workfl ows and 
computer systems, (2) the acceptability by the 
fi nal users (user experience) and (3) the capabil-
ity of keeping DSS up to date [ 40 ]. 
 In the case of GB, the fulfi lment of these 
requirements is even more challenging due to the 
wide variety of multidisciplinary users that will 
interact with the DSS; the need for acquiring, 
integrating and processing a wide variety of com-
plex clinical information (ranging from molecu-
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lar data to multi-parametric stacks of images); 
and the need for covering the whole management 
of GB patients including surgery and RT plan-
ning and CHTH assessment. 
 A tentative schema of how the proposed DSS 
could be integrated in a clinical scenario is pre-
sented in Fig.  16.3 . In this fi gure, we can see (1) 
how the DSS is integrated with the hospital clini-
cal information systems, (2) how the results of 
the DSS are presented to the actors involved in 
the GB patient management by using specialised 
EHR-based visualisation templates and dedicated 
multidisciplinary DSS interface for tumour board 
meetings and (3) the structure of the DSS 
architecture.
 In the following subsection, we will detail our 
approach to overcome the above section barriers: 
16.6.1  Integrating the DSS 
into Clinical Workﬂ ows 
and Computer Systems 
 In order to facilitate the adoption of a DSS for 
GB management, it is critical to implement the 
mechanisms to accomplish the semantic interop-
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erability and complete integration with the exist-
ing hospital information systems. Following the 
interoperability standards and IHE profi les, we 
will ensure the integration and communication 
with different IT products already established in 
the IT infrastructure of the hospitals, enabling 
data capture from existing RIS/pathology/LIS/
EHR systems. From our previous experience, 
this facilitates the adoption of the system at end-
user level by presenting an already familiar user 
interface, reducing the requirements for manual 
data recording as well as the elimination of 
errors in the management of complex data by 
means of automation and integration at both 
hardware and software boundaries. 
 Moreover, it is important to make the DSS 
results accessible to clinicians at the moment 
when decisions are taken. To do this, we propose 
a double strategy consisting on the development 
of (1) highly visual user interfaces tailored for 
each of the multiple hospital areas involved in the 
tumour treatment and (2) an interactive interface 
and automatic reports for the multidisciplinary 
meetings. 
 As a result, the DSS will be fully integrated in 
the hospital workfl ows by means of the IHE pro-
fi les, which will ensure the sharing of the com-
plete information, as well as the control and 
coordination of all the medical services involved 
in the GB management. 
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16.6.2  The Acceptability by the End 
Users 
 One of the major reasons why so many DSS are 
not used in clinical practice is that they lack pos-
itive user experience. Thus, the design of the 
graphical user interface (GUI) is of paramount 
importance in any healthcare tool and DSS 
development since it is the steering wheel. One 
could say that the GUI is actually as important as 
the accuracy of the algorithm and it should be 
intuitive and user-friendly and fulfi l the needs of 
the user(s). 
 In the medical fi eld, we are witnessing the situ-
ation that with more and more specialised exami-
nations, tests and monitoring, physicians are faced 
with a signifi cant amount of different but related 
pieces of information on each patient. Moreover, 
medical work is collaborative. Thus, for a patient 
with a brain tumour, several medical specialties 
and competences (i.e. neurologists, neurosur-
geons, radiologists, oncologists, radiotherapists, 
(neuro)pathologists and clinical psychologists) 
must gather in several multidisciplinary team 
meetings (i.e. tumour board meetings), to present 
their fi ndings and collaboratively discuss the 
diagnosis, treatment and follow-up. Although 
these tumour board meetings are part of the 
healthcare work process, there is room for 
improvement, particularly by tools that would 
facilitate the multidisciplinary meetings’ fl ow and 
the access to multiscale information and would 
support the medical decision. 
 Identifying how technology can improve spe-
cialist interactions and enhance awareness at 
multidisciplinary meetings delivers real benefi ts 
[ 41 ]. In this chapter, we aim to design a GUI that 
will improve patient information visualisation 
and the interaction in tumour board meetings. 
 There have been a number of research studies 
for the improvement of displaying medical infor-
mation when dealing with multiscale informa-
tion. In [ 42 ], it is shown that using advanced 
visualisation techniques helps clinicians in 
improving their work process. Moreover, in [ 43 ], 
it is demonstrated that improved patient informa-
tion visualisation is given by showing details 
prominently and presenting overviews. 
 Due to the extraordinary boost of technology 
in the fi eld of human-machine devices, special 
attention was given in the last years to human- 
machine interaction and therefore to the user 
interface design. A number of diverse methodol-
ogies outlining techniques for human-computer 
interaction design have emerged in the last years. 
Among them UX methodology is the most popu-
lar as it is the best approach for evaluating how 
the user perceives the system before, during and 
after interacting with it. UX methodology is very 
intuitive and user-friendly and therefore highly 
recommended in clinics as several studies sug-
gest that user involvement is crucial to a success-
ful design and implementation of a successful 
tool for healthcare (see [ 44 ]). To avoid a top- 
down approach of designing a GUI for health-
care, close collaboration is needed between 
designers, implementers and the end users. 
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